Oxford Science Enterprises

Porpoise Power is a company that specializes in developing tidal energy systems. Their innovative technology, inspired by the swimming mechanics of dolphins and whales, uses oscillating hydrofoils to harness the power of tidal streams. This unique approach allows the company to generate sustainable electricity at a relatively low cost and minimal environmental impact, even at medium tidal speeds.

Mode Labs specializes in developing and manufacturing low-cost, portable, real-time chemical sensors. Utilizing micron-scale quantum technology, their sensors are designed to speciate and quantify pollutants in natural waterways, offering lab-grade sensitivity with plug-and-play functionality. This enables clients to deploy robust, miniaturized, and scalable sensors remotely, providing continuous, real-time data.

Seloxium is a company focused on transforming the mining, refining, and industrial sectors by providing innovative solutions for wastewater management. Utilizing advanced selective flocculation technology, Seloxium enables the efficient extraction of valuable metals from wastewater and mine tailings. This process not only recovers high-purity metals but also significantly reduces the carbon footprint typically associated with metal extraction. By turning wastewater into a sustainable resource, Seloxium helps its clients meet their environmental and social governance (ESG) goals while simultaneously minimizing the presence of harmful metals in the environment. The company's approach represents a significant advancement in the quest for more sustainable practices within resource-intensive industries.

Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

Salience Labs specializes in developing hybrid photonic-electronic chips aimed at enhancing AI data center infrastructure. The company emerged from extensive research at the University of Oxford and the University of Münster, focusing on silicon photonics to meet the increasing demands of AI workloads. Salience Labs' flagship product is an optical switch that enables all-optical networking between compute nodes, effectively addressing data movement bottlenecks. This innovation provides low-latency, high-bandwidth networking, which accelerates job completion while minimizing power consumption and costs. Additionally, the company offers high-speed multi-chip processors that integrate photonics with standard electronics, allowing for on-chip processing using photons instead of electrons. This approach significantly reduces power requirements and supports a transformation in the hardware necessary to harness the full potential of AI technologies.

Neu Health is a developer of a smartphone-based clinical platform designed to enhance personalized care for patients with Parkinson's disease and dementia. The company's innovative platform leverages artificial intelligence to monitor and interpret digital measures of clinically relevant symptoms. By optimizing condition management, Neu Health aims to reduce the burden on clinicians while improving patient outcomes. This approach enables healthcare providers and caregivers to deliver more efficient and effective care, addressing the challenges associated with managing these complex neurological conditions.

FluoRok is a company focused on transforming the production of fluorochemicals through innovative technology. It has developed a patented approach that eliminates the need for dangerous hydrofluoric acid in the manufacturing process. This technology provides a safer, more sustainable, and cost-effective method for producing fluorochemicals, catering to industries such as agrochemicals, pharmaceuticals, and materials. By offering a cleaner alternative, FluoRok aims to enhance access to essential fluorochemicals while promoting environmental sustainability and safety in chemical production.

Iota Sciences Ltd. is a company focused on developing tools and technologies that utilize fluid shaping technologies to enhance drug discovery processes. Founded in 2016 and headquartered in Oxford, United Kingdom, the company specializes in creating fluidic mu-wells specifically designed for cell biology applications. Through its innovative approach, Iota Sciences aims to provide unique capabilities that facilitate advancements in the understanding and manipulation of cellular processes, thereby accelerating research and development in the pharmaceutical sector.

PQShield Ltd is a company based in Oxford, United Kingdom, that specializes in providing quantum-secure cryptographic solutions to enhance cybersecurity in the face of emerging quantum computing threats. Founded in 2018, PQShield develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors; PQSDK, which integrates post-quantum primitives with the OpenSSL API; and PQE2E, a software development toolkit for secure data messaging using post-quantum algorithms. The company focuses on securing technology infrastructures across various domains, offering both ready-made and customized intellectual property to facilitate the transition from traditional cryptographic standards, such as RSA and Elliptic Curve, to quantum-safe alternatives. Through its innovations, PQShield aims to safeguard sensitive data and communications, contributing to the advancement of robust digital security in an evolving technological landscape.

Fractile is a technology company specializing in the development of advanced AI chips. Their innovative hardware is designed to significantly accelerate the inference process of large language models, which is currently hindered by the slow movement of network weights from memory to the chip. Fractile's groundbreaking approach, which integrates computation with memory, eliminates this bottleneck, enabling faster and more efficient AI model inference. This allows AI developers to run the largest language models more quickly and explore new capabilities in AI applications.

Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Oxford Endovascular is focused on developing an innovative biotechnology device aimed at treating brain aneurysms. The company's technology employs a laser-cut metal alloy that utilizes shape-memory properties, enabling it to be inserted into a patient's brain via a catheter. Once in place, the device expands into a small mesh tube, commonly referred to as a flow diverter, which conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, promoting healing and reducing the risk of rupture. By utilizing advanced engineering techniques, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for individuals affected by this serious condition.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Oxford Quantum Circuits is a developer of advanced quantum computing technology that aims to address significant global challenges, such as climate change and drug discovery. The company focuses on creating unique superconducting circuits essential for quantum computation, ensuring high-quality qubit control and maintaining operational efficiency. Their quantum computers are fully integrated units, comprising the necessary control systems, hardware, and software, which enable customers to enhance their operations, innovate new methodologies, and tackle pressing issues. Through its pioneering technology, Oxford Quantum Circuits contributes to groundbreaking advancements that hold the potential for transformative impacts across various industries.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Prolific is a company that offers an online platform for researchers seeking to recruit survey participants efficiently and ethically. By connecting a diverse global audience, Prolific enables users to quickly submit surveys and specify their target demographics, facilitating the collection of high-quality psychological and behavioral data in a matter of minutes. The company's mission is to enhance accessibility to trustworthy data, ultimately supporting improved human knowledge and informed decision-making. Through its innovative approach, Prolific empowers researchers by providing a reliable and streamlined data collection process.

Beacon Therapeutics is a biotechnology company focused on developing gene therapies for rare retinal diseases that cause blindness. Utilizing its proprietary platform, Beacon aims to restore and improve vision in patients suffering from these debilitating conditions. Currently operating at the clinical stage, the company's primary focus lies within ophthalmology, with the goal of transforming lives by treating severe eye diseases.

Caristo Diagnostics Limited is a pioneering company based in Oxford, United Kingdom, specializing in the development of artificial intelligence-driven software for cardiac diagnostics. Founded in 2018 as a spin-out from the University of Oxford, Caristo focuses on predicting and diagnosing coronary artery disease, heart attacks, strokes, and diabetes through its advanced imaging-based platforms. Its flagship product, the CaRi-Heart technology, utilizes AI algorithms to analyze routine cardiac computed tomography (CCTA) scans, enabling the measurement of the Fat Attenuation Index (FAI), a novel biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical information, including individual risk assessments and coronary plaque characterization. The technology has received CE Mark certification and is currently designated for research use in the U.S. Caristo's innovations have garnered significant validation in respected medical journals and have been supported by various government grants, demonstrating its potential to transform cardiac care by enhancing the prediction and prevention of heart-related events globally.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

QuantrolOx specializes in developing automated machine learning-based control software for quantum technologies, focusing on the tuning, stabilization, and optimization of qubits. By providing robust software solutions, the company aids quantum scientists in achieving stable platforms for experimentation, which enhances the effectiveness of quantum computing applications. This innovative approach allows clients to utilize more cost-effective quantum infrastructure while efficiently implementing standard quantum computing technologies in their operations.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Quantum Motion Technologies specializes in developing a universal quantum computer utilizing silicon-based architectures compatible with CMOS processes. The company focuses on creating scalable quantum computing technology that addresses key challenges such as fault tolerance and qubit redundancy. By leveraging complementary metal-oxide semiconductor technology, Quantum Motion aims to enhance the density of qubits, enabling the construction of larger and more efficient quantum systems. This advancement is intended to facilitate significant improvements in quantum computing applications, assisting clients in the quantum technology sector to minimize errors and overcome critical challenges in quantum information and technology.

Archangel Lightworks is a laser communications company specializing in the development of secure, wireless technology aimed at addressing the challenges of space-ground connectivity. The company focuses on creating innovative laser transmission systems that facilitate efficient communication within the aerospace sector. Its product offerings include space terminals designed for satellites, air terminals for drones and manned aircraft, and ground communications terminals. By providing these advanced solutions, Archangel Lightworks enables resilient connectivity that overcomes the limitations of traditional radio communications, which are often bandwidth-constrained and less secure.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Amber Therapeutics is a biotechnology company that specializes in developing advanced bioelectrical therapies aimed at treating functional disorders of the peripheral nervous system. The company creates a bioelectronic platform that delivers closed-loop bioelectrical treatments, which can sense and adapt to the patient's needs while also providing stimulation. By focusing on conditions such as mixed urinary incontinence, Amber Therapeutics seeks to enhance clinical efficacy and patient outcomes through innovative approaches that emphasize the peripheral nervous system rather than the central nervous system. Its technology has the potential to significantly improve treatment methods and overall patient care in targeted disease areas.

Oxford Ionics is a quantum computing startup focused on developing high-performance quantum computers through the use of trapped-ion technology. The company combines advanced qubit designs with a noiseless electronic control system, allowing for accurate and reliable manipulation of qubits. This technology enables the parallel control of interconnected qubit registers, ensuring performance is not compromised. By employing standard semiconductor fabrication methods, Oxford Ionics aims to create scalable quantum chips that enhance computational capabilities for complex problem-solving. The company's innovations position it to significantly advance the quantum computing market, providing clients with dependable solutions for high-performance applications.

BehaVR, LLC is a healthcare technology company founded in 2016 and based in Elizabethtown, Kentucky. The company specializes in developing digital therapeutics that leverage virtual reality to address behavioral health challenges, particularly in the context of chronic diseases. BehaVR's platform aims to enhance skills such as stress resilience, emotional regulation, and self-efficacy, enabling individuals to better manage their conditions, adhere to treatment plans, and ultimately improve their overall health outcomes. Through its innovative approach, BehaVR seeks to bridge the gap between behavioral health and chronic disease management.

Osler Diagnostics is a UK-based company focused on providing accessible and accurate health diagnostics. Founded in 2017 as a spin-off from the University of Oxford, the company has leveraged extensive research in portable diagnostic technologies, originally stemming from the development of the blood glucose sensor. Its flagship product, the Osler Origin, is a portable laboratory capable of delivering lab-quality diagnostics anytime and anywhere, enabling individuals to conduct tests for a variety of health biomarkers using just a drop of blood. This innovative approach aims to decentralize healthcare, making it easier for users to monitor their health and make informed decisions, ultimately supporting healthier and longer lives. Osler Diagnostics is headquartered in Oxford, UK, and aims to serve all major healthcare settings globally.

Util is a company that specializes in sustainability intelligence technology, aimed at providing investors with an objective, evidence-based perspective on corporate impact. By leveraging big data and machine learning, Util aggregates and analyzes a wide array of stakeholder-related data, transforming it into a quantifiable metric termed the "annual value generated." This innovative approach allows responsible investors to assess and report on both financial and non-financial performance, thereby redefining investment evaluation criteria. Util's methodology transcends conventional ESG metrics, presenting a comprehensive view of companies as complex value generators. The company’s solutions are applicable to all listed securities, catering to investment managers seeking advanced analytical tools that align with traditional financial reporting efficiencies. Currently, Util collaborates with two investment manager partners that collectively oversee $130 billion in assets, enhancing the development of its unique methodologies and products.

Nucleome Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, founded in 2019. The company focuses on decoding the "dark matter" of the human genome, which comprises over 95% of disease-linked genetic variants that have not yet been fully explored. By leveraging a unique platform that creates high-resolution three-dimensional genome structure maps and employs machine learning techniques, Nucleome aims to link these genetic variants to gene functions and map disease pathways. This innovative approach facilitates the functional validation of variants in primary cell types, enabling the discovery and development of novel therapeutics. Initially concentrating on lymphocytes and autoimmune diseases, Nucleome Therapeutics seeks to establish a robust pipeline of drug assets along with corresponding biomarkers to improve patient outcomes through genetically guided therapeutics.

Opsydia Limited, established in 2017 and based in Begbroke, UK, specializes in manufacturing advanced laser marking technology. This technology enables the creation of permanent, invisible structures such as serial numbers, images, and cryptographic data within transparent materials like diamonds, glass, polymers, and plastics without altering their surface or integrity. Opsydia's innovative solution aims to disrupt various industries by enhancing security, traceability, and authenticity in transparent materials.

Oxford Quantum Circuits is a developer of advanced quantum computing technology that aims to address significant global challenges, such as climate change and drug discovery. The company focuses on creating unique superconducting circuits essential for quantum computation, ensuring high-quality qubit control and maintaining operational efficiency. Their quantum computers are fully integrated units, comprising the necessary control systems, hardware, and software, which enable customers to enhance their operations, innovate new methodologies, and tackle pressing issues. Through its pioneering technology, Oxford Quantum Circuits contributes to groundbreaking advancements that hold the potential for transformative impacts across various industries.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

ORCA Computing Limited, founded in 2019 and located in Oxford, United Kingdom, specializes in the development of quantum computers utilizing photonic technology. The company is focused on creating scalable and flexible quantum computing systems powered by quantum memories, which enhance the storage and synchronization of quantum operations. By combining proprietary memory technology with standard telecom and optical fiber components, ORCA Computing offers a novel modular architecture that leverages the full potential of photonic computing. This innovative approach aims to unlock advanced applications across various industries, accelerate technological innovation, and significantly improve performance in quantum computing.

BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Salience Labs specializes in developing hybrid photonic-electronic chips aimed at enhancing AI data center infrastructure. The company emerged from extensive research at the University of Oxford and the University of Münster, focusing on silicon photonics to meet the increasing demands of AI workloads. Salience Labs' flagship product is an optical switch that enables all-optical networking between compute nodes, effectively addressing data movement bottlenecks. This innovation provides low-latency, high-bandwidth networking, which accelerates job completion while minimizing power consumption and costs. Additionally, the company offers high-speed multi-chip processors that integrate photonics with standard electronics, allowing for on-chip processing using photons instead of electrons. This approach significantly reduces power requirements and supports a transformation in the hardware necessary to harness the full potential of AI technologies.

OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Scenic Biotech, established in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies to combat cancer and rare genetic diseases. The company's core focus is to identify and harness disease-suppressing genes, which can act as an "off-switch" for genetic disorders, thereby creating novel drug targets and therapies. By leveraging genomics, Scenic Biotech aims to revolutionize the treatment of severe diseases by tackling them at the genetic level.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

PQShield Ltd is a company based in Oxford, United Kingdom, that specializes in providing quantum-secure cryptographic solutions to enhance cybersecurity in the face of emerging quantum computing threats. Founded in 2018, PQShield develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors; PQSDK, which integrates post-quantum primitives with the OpenSSL API; and PQE2E, a software development toolkit for secure data messaging using post-quantum algorithms. The company focuses on securing technology infrastructures across various domains, offering both ready-made and customized intellectual property to facilitate the transition from traditional cryptographic standards, such as RSA and Elliptic Curve, to quantum-safe alternatives. Through its innovations, PQShield aims to safeguard sensitive data and communications, contributing to the advancement of robust digital security in an evolving technological landscape.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

natcap is a nature intelligence company that provides report and act on impacts and dependencies on nature.

ONI is a pioneering company in super-resolution microscopy, dedicated to making advanced imaging technology accessible to researchers. Its flagship product, the Nanoimager, is the first benchtop-sized super-resolution microscope, significantly enhancing usability and precision in biological research. This innovative device allows users to access various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by leading laboratories worldwide, including institutions such as the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize super-resolution fluorescence imaging, thereby accelerating scientific discovery and aiding in disease research by enabling researchers to visualize and comprehend the intricate details of life at the molecular level. Recognized for its contributions to the field, ONI has received accolades for its innovative approach and commitment to enhancing the effectiveness and accessibility of scientific research.

Alethiomics is a pre-clinical biotechnology company focused on developing innovative treatments for blood cancers. It employs single-cell multi-omic technology to uncover novel insights into disease mechanisms and identify targeted therapies, aiming to improve patient outcomes for myeloproliferative neoplasms and other related blood disorders.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Rey is a membership-based, on-demand mental health company on a mission to revolutionize mental health and wellness by improving access to personalized services through technology.

Orbit Discovery Ltd. is a biotechnology company based in Oxford, United Kingdom, that specializes in peptide display technology for the identification of peptide drugs aimed at treating chronic diseases. Established in 2015, the company utilizes an innovative in vitro display platform that links randomized peptide sequences to their encoding DNA on small beads, facilitating the screening of potential peptide therapeutics. This approach allows for the discovery of peptides that can offer the specificity and efficacy of larger biologic molecules while maintaining the advantages of smaller molecules, such as reduced dosage and lower manufacturing costs. Orbit Discovery's technology enhances the drug development process by enabling high-throughput screening of peptide candidates, thus supporting both internal drug discovery initiatives and collaborative research efforts.

Omega Crop is a company that specializes in crop modeling, integrating geo-statistics with a comprehensive data ecosystem to enhance agricultural decision-making. By leveraging a diverse array of data sources, including satellites, drones, and hyper-local weather information, Omega Crop monitors and evaluates the performance of farming operations. Their technology offers detailed diagnostics of fields, enabling farmers to anticipate crop performance risks and address issues in real-time. This approach not only helps in making informed decisions but also creates opportunities for growers to optimize yields, ultimately contributing to global food production.

Oxford Endovascular is focused on developing an innovative biotechnology device aimed at treating brain aneurysms. The company's technology employs a laser-cut metal alloy that utilizes shape-memory properties, enabling it to be inserted into a patient's brain via a catheter. Once in place, the device expands into a small mesh tube, commonly referred to as a flow diverter, which conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, promoting healing and reducing the risk of rupture. By utilizing advanced engineering techniques, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for individuals affected by this serious condition.

Caristo Diagnostics Limited is a pioneering company based in Oxford, United Kingdom, specializing in the development of artificial intelligence-driven software for cardiac diagnostics. Founded in 2018 as a spin-out from the University of Oxford, Caristo focuses on predicting and diagnosing coronary artery disease, heart attacks, strokes, and diabetes through its advanced imaging-based platforms. Its flagship product, the CaRi-Heart technology, utilizes AI algorithms to analyze routine cardiac computed tomography (CCTA) scans, enabling the measurement of the Fat Attenuation Index (FAI), a novel biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical information, including individual risk assessments and coronary plaque characterization. The technology has received CE Mark certification and is currently designated for research use in the U.S. Caristo's innovations have garnered significant validation in respected medical journals and have been supported by various government grants, demonstrating its potential to transform cardiac care by enhancing the prediction and prevention of heart-related events globally.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapeutics and vaccines aimed at treating and preventing infectious diseases and cancer. The company utilizes proprietary modified simian adenoviral vectors, specifically ChAdOx1 and ChAdOx2, along with the Modified Vaccinia Ankara (MVA) boost vector, both of which are designed to be safe and non-replicative in humans. This combination approach has demonstrated the ability to generate significantly higher levels of CD8+ T cells compared to other methodologies. Barinthus Biotherapeutics maintains a diverse pipeline that includes both clinical and preclinical therapeutic programs targeting solid tumors, viral infections, and prophylactic viral vaccines. In collaboration with the University of Oxford, the company co-invented a COVID-19 vaccine that has received approval for use in various regions worldwide.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

SpyBiotech Limited is a biotechnology company based in Oxford, United Kingdom, founded in 2017. The company specializes in the development of molecular superglue technology, which is utilized to create next-generation vaccines. This proprietary platform allows for the bonding of antigens to viruses and other particles, facilitating the rapid development of vaccines targeting a variety of diseases. By employing this innovative approach, SpyBiotech aims to enhance vaccine efficacy and reduce the time required for development, thereby providing medical institutions and research centers with advanced solutions for combating bacterial infections and other health challenges.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Living Optics Limited is a company focused on designing and developing compact hyperspectral imaging cameras and related software, aimed at revolutionizing the imaging market. Founded in 2019 and headquartered in Oxford, United Kingdom, with additional offices in Taiwan, Living Optics seeks to make hyperspectral imaging accessible for a variety of consumer products, medical devices, and industrial applications. The company's innovative technology captures data that is typically invisible to the human eye and conventional cameras, offering an affordable and portable solution for users, including computer vision developers and scientists. This allows clients to integrate spectral imaging data into new applications and research, broadening the potential uses of their groundbreaking imaging technology.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

T-Cypher Bio is an early-stage biotechnology company focused on developing T-cell receptor (TCR)-based therapeutics. The company aims to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. T-Cypher addresses challenges in identifying therapeutically relevant targets and TCRs through its integrated platform, D-Cypher. This platform enables the generation of target screening libraries to identify functionally defined T-cell clones directly from disease tissues, providing an end-to-end approach to cell therapy development and patient treatment for a broad range of indications.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry, a technology that enables the analysis of biomolecules. The company's flagship product, Refeyn One, utilizes single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. Refeyn's innovative optical technology allows researchers to measure the mass of individual molecules across various biologically relevant concentrations without the need for labels, providing both quality-control instruments and advanced research tools. This capability enhances the understanding of biomolecular behavior in their native states, facilitating significant advancements in the field of biochemistry and molecular biology.

ORCA Computing Limited, founded in 2019 and located in Oxford, United Kingdom, specializes in the development of quantum computers utilizing photonic technology. The company is focused on creating scalable and flexible quantum computing systems powered by quantum memories, which enhance the storage and synchronization of quantum operations. By combining proprietary memory technology with standard telecom and optical fiber components, ORCA Computing offers a novel modular architecture that leverages the full potential of photonic computing. This innovative approach aims to unlock advanced applications across various industries, accelerate technological innovation, and significantly improve performance in quantum computing.

PQShield Ltd is a company based in Oxford, United Kingdom, that specializes in providing quantum-secure cryptographic solutions to enhance cybersecurity in the face of emerging quantum computing threats. Founded in 2018, PQShield develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors; PQSDK, which integrates post-quantum primitives with the OpenSSL API; and PQE2E, a software development toolkit for secure data messaging using post-quantum algorithms. The company focuses on securing technology infrastructures across various domains, offering both ready-made and customized intellectual property to facilitate the transition from traditional cryptographic standards, such as RSA and Elliptic Curve, to quantum-safe alternatives. Through its innovations, PQShield aims to safeguard sensitive data and communications, contributing to the advancement of robust digital security in an evolving technological landscape.

Oxford Ionics is a quantum computing startup focused on developing high-performance quantum computers through the use of trapped-ion technology. The company combines advanced qubit designs with a noiseless electronic control system, allowing for accurate and reliable manipulation of qubits. This technology enables the parallel control of interconnected qubit registers, ensuring performance is not compromised. By employing standard semiconductor fabrication methods, Oxford Ionics aims to create scalable quantum chips that enhance computational capabilities for complex problem-solving. The company's innovations position it to significantly advance the quantum computing market, providing clients with dependable solutions for high-performance applications.

Base Genomics Limited, established in 2019 and headquartered in Oxford, UK, specializes in epigenetics technology development. The company's core innovation is TAPS (TET-assisted pyridine borane sequencing), a method that enables simultaneous analysis of genetic and epigenetic information at base resolution from DNA samples. Unlike traditional bisulfite sequencing, TAPS preserves DNA integrity and sequence complexity, yielding more data for analysis while reducing costs. This technology has applications in early cancer detection, minimal residual disease (MRD) analysis, patient monitoring, biomarker discovery, and infectious disease diagnostics, including COVID-19. As of October 2020, Base Genomics operates as a subsidiary of Exact Sciences Corporation.

Oxford Flow Ltd. is a UK-based company founded in 2015 that specializes in designing, manufacturing, and supplying pressure control equipment. The company’s product range includes gas regulators, water pressure reducing valve sets, silencers, and pilots, catering to various industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow focuses on developing small, light, and reliable valves that simplify systems, ensuring a consistent supply of potable water while adhering to stringent water quality and leakage control standards. By combining academic expertise with industry experience, the company aims to deliver practical solutions that enhance operational efficiency and reduce environmental impact, all while maintaining cost-effectiveness and high performance. Each device is rigorously tested and refined based on customer feedback, demonstrating proven reliability even in challenging conditions.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Quantum Motion Technologies specializes in developing a universal quantum computer utilizing silicon-based architectures compatible with CMOS processes. The company focuses on creating scalable quantum computing technology that addresses key challenges such as fault tolerance and qubit redundancy. By leveraging complementary metal-oxide semiconductor technology, Quantum Motion aims to enhance the density of qubits, enabling the construction of larger and more efficient quantum systems. This advancement is intended to facilitate significant improvements in quantum computing applications, assisting clients in the quantum technology sector to minimize errors and overcome critical challenges in quantum information and technology.

BibliU Ltd is a software platform developed to provide online access to textbooks and educational materials, catering primarily to colleges and universities. Founded in 2014 and headquartered in London, with an additional office in New York, BibliU offers a comprehensive digital content management solution that allows students to access textbooks and supplementary courseware from various devices anytime and anywhere. The platform boasts partnerships with thousands of publishers and open educational resource providers, making millions of digital resources available. Key features include instant access to course content, a discovery search tool, offline support, and analytics, along with synchronized highlights and comments to enhance the learning experience. Overall, BibliU aims to blend academic accessibility with affordability and automation in education.

Living Optics Limited is a company focused on designing and developing compact hyperspectral imaging cameras and related software, aimed at revolutionizing the imaging market. Founded in 2019 and headquartered in Oxford, United Kingdom, with additional offices in Taiwan, Living Optics seeks to make hyperspectral imaging accessible for a variety of consumer products, medical devices, and industrial applications. The company's innovative technology captures data that is typically invisible to the human eye and conventional cameras, offering an affordable and portable solution for users, including computer vision developers and scientists. This allows clients to integrate spectral imaging data into new applications and research, broadening the potential uses of their groundbreaking imaging technology.

Perspectum is a global medical technology company dedicated to enhancing patient care for individuals with liver disease, diabetes, and cancer. The company specializes in precision medicine, utilizing advanced imaging and genetics to provide clinicians with quantitative health assessments. This approach enables early detection, accurate diagnosis, and targeted treatment of complex health issues. Perspectum's team comprises physicians, biomedical scientists, engineers, and technologists who work together to manage these conditions at scale, empowering both patients and healthcare providers.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

YASA Motors Ltd. specializes in the manufacture of axial flux motors and generators tailored for electric and hybrid vehicles, as well as for various industrial applications. Established in 2009, the company produces a range of electric motors, including low-speed high-torque models and those designed for higher speed and power applications. YASA's innovative motor technology is particularly suited for sectors such as automotive, aerospace, marine, and construction equipment, where it addresses needs for traction, propulsion, and power generation. In addition to standard products, YASA offers custom motor solutions and consultancy services, which encompass electrical architecture design and thermal modeling. The company operates from its headquarters in Yarnton, United Kingdom, where it focuses on developing efficient, lightweight motors that meet the increasing global demand for reduced emissions and improved energy efficiency across multiple industries.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.

Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.

Oxford Semantic Technologies is a company founded in 2017 as a spin-out from the University of Oxford, specializing in the development of RDFox, an advanced knowledge graph and semantic reasoning engine. The company emerged from research initiated in 2011 at the University’s Computer Science Department, aimed at creating a high-performance solution for data-intensive applications. RDFox leverages patented modern computing techniques to provide rapid responses to complex queries, thus enabling enterprise applications for various prestigious partners. The engine is designed to harness the capabilities of modern multi-core architectures, simplifying the querying process for domain experts and reducing reliance on IT specialists. Additionally, RDFox includes features that explain how answers to queries are derived, enhancing clients' ability to validate their results and ensuring confidence in the insights generated.

Albus Health is a startup originating from the University of Oxford, focusing on the development of an intelligent nocturnal monitoring platform for personalized home health monitoring. The platform enables passive, contactless, and objective tracking of various symptoms and environmental metrics. This innovative system is designed primarily for use in clinical trials by leading pharmaceutical companies, facilitating the monitoring of nocturnal symptoms and aiding in the prediction of respiratory emergencies. By providing detailed insights into patient conditions, Albus Health's technology supports pharmaceutical firms in optimizing their clinical studies while enhancing revenue potential.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Covatic Ltd is a Birmingham-based company, incorporated in 2016, that specializes in broadcast personalization software. It focuses on developing a consumer insight platform that enhances user engagement by utilizing mobile-based algorithms for smart personalization in applications. Covatic's technology enables clients to connect with their audiences effectively by identifying optimal engagement times and methods without compromising personal data privacy. This approach allows businesses to gather and tailor content for their target users, fostering a more personalized experience without requiring the exposure of sensitive information. With an additional office in London, Covatic aims to innovate in the field of application personalization.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

Caristo Diagnostics Limited is a pioneering company based in Oxford, United Kingdom, specializing in the development of artificial intelligence-driven software for cardiac diagnostics. Founded in 2018 as a spin-out from the University of Oxford, Caristo focuses on predicting and diagnosing coronary artery disease, heart attacks, strokes, and diabetes through its advanced imaging-based platforms. Its flagship product, the CaRi-Heart technology, utilizes AI algorithms to analyze routine cardiac computed tomography (CCTA) scans, enabling the measurement of the Fat Attenuation Index (FAI), a novel biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical information, including individual risk assessments and coronary plaque characterization. The technology has received CE Mark certification and is currently designated for research use in the U.S. Caristo's innovations have garnered significant validation in respected medical journals and have been supported by various government grants, demonstrating its potential to transform cardiac care by enhancing the prediction and prevention of heart-related events globally.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.